Advanced Cellular Blueprint

Advanced Cellular Blueprint: Assessment Panel Specifications

Clinical Q&A: Advanced Cellular Blueprint

How does epigenetic biological age differ from chronological age, and why does it matter more?

Chronological age is simply the number of years since birth. Epigenetic biological age measures chemical modifications to DNA — specifically methylation patterns at CpG sites — that accumulate at rates determined by lifestyle, environment, and disease burden. The GrimAge clock, derived from 1,030 individuals and validated in over 10,000 subjects, predicts time-to-death more accurately than any single traditional biomarker. A 5-year epigenetic age acceleration (biological age 5 years older than chronological age) corresponds to approximately a 16–21% increase in all-cause mortality risk. Conversely, measurable epigenetic age deceleration has been demonstrated following caloric restriction, aerobic exercise training, and certain pharmacological interventions, confirming these clocks respond to modifiable factors rather than representing fixed genetic fate.

What is cellular senescence and how does SASP contribute to disease progression?

Cellular senescence is a state of permanent cell-cycle arrest — cells that have lost the ability to divide but remain metabolically active and resist apoptosis. Senescent cells accumulate with age and following genotoxic stress (UV, chemotherapy, oxidative damage). They secrete a complex pro-inflammatory milieu termed the Senescence-Associated Secretory Phenotype (SASP): interleukins (IL-6, IL-8), matrix metalloproteinases (MMP-3), growth factors (GDF-15), and TNF-alpha. This SASP propagates senescence to neighbouring cells, disrupts tissue architecture, drives chronic sterile inflammation (inflammageing), and creates a tumour-permissive microenvironment. p16INK4a mRNA expression in peripheral blood mononuclear cells is the most validated circulating senescence biomarker, rising exponentially from age 35 onwards. Emerging senolytics (dasatinib + quercetin, fisetin) specifically clear senescent cells and have shown preclinical efficacy across multiple age-related pathologies.

What NAD+ level warrants intervention, and which repletion strategy has the strongest evidence?

Intracellular NAD+ measured by HPLC-MS in whole blood declines from approximately 40–50 micromolar at age 30 to 20–25 micromolar by age 60 — a ~50% reduction that impairs SIRT1-mediated deacetylation, PARP1-dependent DNA repair, and CD38-regulated calcium signalling. Functional NAD+ insufficiency presents as declining metabolic flexibility, impaired stress response, and accumulating genomic instability. Clinical trials support NMN (nicotinamide mononucleotide) at 250–900 mg/day increasing whole-blood NAD+ by 38–90% over 12 weeks (Yoshino et al., 2021; Igarashi et al., 2022). NR (nicotinamide riboside) at 300–1,000 mg/day similarly raises NAD+ 40–60%. The Advanced Cellular Blueprint baseline enables personalised dosing and monitoring of NMN/NR supplementation efficacy, transforming supplementation from guesswork into measurable biochemistry.

How is telomere length interpreted clinically, and what lifestyle factors most reliably preserve it?

Telomere length is reported as a T/S ratio (telomere repeat copy number to single-copy gene ratio) and compared against age-sex-matched population percentiles. Leukocyte telomere length in the lowest quartile for age is associated with 1.5–1.9× increased risk of cardiovascular disease and 1.3× all-cause mortality. Critically, intra-individual rate of telomere attrition over serial measurements predicts disease trajectory better than a single cross-sectional value. Lifestyle interventions with the strongest evidence for telomere preservation include: vigorous aerobic exercise (VO2 max training) reducing attrition rate ~30% in RCT data; Mediterranean-pattern diet reducing attrition vs. Western diet; stress reduction via MBSR reducing cortisol-mediated telomere shortening; and TA-65 (cycloastragenol, a telomerase activator) with modest but consistent evidence in human trials. The Blueprint provides a baseline from which intervention efficacy can be tracked at 6–12-month intervals.

What does the composite biological age index measure and how is the longevity protocol personalised?

The composite biological age index integrates all six domain results into a single weighted score using Singapore-population reference data, producing: (1) an overall biological age in years, (2) domain-specific Z-scores identifying which systems show the greatest acceleration or deceleration relative to age-matched peers, and (3) a ranked priority list of intervention targets based on the magnitude and modifiability of each domain's deviation. The personalised longevity protocol — curated by EMIS+ registered nurses with post-graduate training in longevity medicine — translates these findings into a structured 90-day intervention plan addressing nutrition (macronutrient periodisation, specific dietary patterns), exercise prescription (volume, intensity, modality tailored to cardiometabolic and mitochondrial findings), sleep architecture optimisation, evidence-ranked supplementation, and medical referral pathways where domain results indicate clinical intervention thresholds.

Regulatory & Standards Framework: Laboratory services performed under ISO 15189:2022 (Medical laboratories — Requirements for quality and competence) and ISO 22870:2016 (Point-of-care testing). Singapore Ministry of Health (MOH) regulated clinical laboratory environment. DNA methylation analyses validated per ISO/IEC 17025:2017 testing laboratory standards. Mass spectrometry (NAD+ quantification) compliant with CLSI C62-A guidelines for LC-MS/MS. Cardiovascular biomarker methods (Lp(a), ApoB) referenced to WHO International Reference Preparation and IFCC standardisation protocols. GrimAge/PhenoAge epigenetic clocks: Lu AT et al., Nature Aging 2019; Levine ME et al., Aging 2018.